T cell differentiation is a highly regulated, multi-step process necessary for the progressive
establishment of effector functions, immunological memory, and long-term control of …

Adoptive immunotherapy with T cells genetically modified to express chimeric antigen
receptors (CARs) is a promising approach to improve outcomes for cancer patients. While …

Despite their clinical success, chimeric antigen receptor (CAR)-T cell therapies for B cell
malignancies are limited by lengthy, costly and labor-intensive ex vivo manufacturing …

As the targets of chimeric antigen receptor (CAR)–T cells expand to a variety of cancers,
autoimmune diseases, viral infections, and fibrosis, there is an increasing demand for …

Synthetic receptor signalling has the potential to endow adoptively transferred T cells with
new functions that overcome major barriers in the treatment of solid tumours, including the …

Allogeneic hematopoietic cell transplantation (allo-HCT) is an essential therapeutic modality
for patients with hematological malignancies and other blood disorders. Unfortunately, acute …

As an emerging treatment strategy for malignant tumors, chimeric antigen receptor T (CAR-
T) cell therapy has been widely used in clinical practice, and its efficacy has been markedly …

It has been well established that CD8+ T cells serve as effector cells of the adaptive immune
response against tumors, whereas CD4+ T cells either help or suppress the generation of …

CD8+ T cell longevity regulated by metabolic activity plays important roles in cancer
immunotherapy. Although in vitro–polarized, transferred IL-9–secreting CD8+ Tc9 (cytotoxic …

Simple Summary While most cancer immunotherapies have focused on CD8+ T cells as the
main drivers of antitumor immunity, increasing evidence indicates that CD4+ T cells also …